Last reviewed · How we verify

BKM120 and Erlotinib — Competitive Intelligence Brief

BKM120 and Erlotinib (BKM120 and Erlotinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PI3K inhibitor, EGFR tyrosine kinase inhibitor. Area: Oncology.

phase 2 PI3K inhibitor, EGFR tyrosine kinase inhibitor PI3K, EGFR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

BKM120 and Erlotinib (BKM120 and Erlotinib) — SCRI Development Innovations, LLC. BKM120 is a PI3K inhibitor, and Erlotinib is a tyrosine kinase inhibitor targeting EGFR.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BKM120 and Erlotinib TARGET BKM120 and Erlotinib SCRI Development Innovations, LLC phase 2 PI3K inhibitor, EGFR tyrosine kinase inhibitor PI3K, EGFR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PI3K inhibitor, EGFR tyrosine kinase inhibitor class)

  1. SCRI Development Innovations, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BKM120 and Erlotinib — Competitive Intelligence Brief. https://druglandscape.com/ci/bkm120-and-erlotinib. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: